journal
https://read.qxmd.com/read/38484153/abt199-venetoclax-synergism-with-thiotepa-enhances-the-cytotoxicity-of-fludarabine-cladribine-and-busulfan-in-aml-cells
#21
JOURNAL ARTICLE
Benigno C Valdez, Bin Yuan, David Murray, Jeremy L Ramdial, Uday Popat, Yago Nieto, Borje S Andersson
ABT199/venetoclax, an inhibitor of the pro-survival BCL-2 protein, has improved AML treatment. Its efficacy in hematopoietic stem cell transplantation (HSCT), when combined with other chemotherapeutic drugs, has not been thoroughly investigated. The present study demonstrates the synergistic cytotoxicity of ABT199/venetoclax with the DNA alkylator thiotepa (Thio) in AML cells. Cleavage of Caspase 3, PARP1 and HSP90, as well as increased Annexin V positivity, suggest potent activation of apoptosis by this two-drug combination; increased levels of γ-H2AX, P-CHK1 (S317), P-CHK2 (S19) and P-SMC1 (S957) indicate an enhanced DNA damage response...
March 14, 2024: Oncotarget
https://read.qxmd.com/read/38484152/analytical-validation-of-next-personal%C3%A2-an-ultra-sensitive-personalized-circulating-tumor-dna-assay
#22
JOURNAL ARTICLE
Josette Northcott, Gabor Bartha, Jason Harris, Conan Li, Fabio C P Navarro, Rachel Marty Pyke, Manqing Hong, Qi Zhang, Shuyuan Ma, Tina X Chen, Janet Lai, Nitin Udar, Juan-Sebastian Saldivar, Erin Ayash, Joshua Anderson, Jiang Li, Tiange Cui, Tu Le, Ruthie Chow, Randy Jerel Velasco, Chris Mallo, Rose Santiago, Robert C Bruce, Laurie J Goodman, Yi Chen, Dan Norton, Richard O Chen, John M Lyle
We describe the analytical validation of NeXT Personal® , an ultra-sensitive, tumor-informed circulating tumor DNA (ctDNA) assay for detecting residual disease, monitoring therapy response, and detecting recurrence in patients diagnosed with solid tumor cancers. NeXT Personal uses whole genome sequencing of tumor and matched normal samples combined with advanced analytics to accurately identify up to ~1,800 somatic variants specific to the patient's tumor. A personalized panel is created, targeting these variants and then used to sequence cell-free DNA extracted from patient plasma samples for ultra-sensitive detection of ctDNA...
March 14, 2024: Oncotarget
https://read.qxmd.com/read/38484151/g-quadruplex-landscape-and-its-regulation-revealed-by-a-new-antibody-capture-method
#23
JOURNAL ARTICLE
Subhamoy Datta, Manthan Patel, Chakkarai Sathyaseelan, Chandrama Ghosh, Akanksha Mudgal, Divyesh Patel, Thenmalarchelvi Rathinavelan, Umashankar Singh
Our understanding of DNA G-quadruplexes (G4s) from in vitro studies has been complemented by genome-wide G4 landscapes from cultured cells. Conventionally, the formation of G4s is accepted to depend on G-repeats such that they form tetrads. However, genome-wide G4s characterized through high-throughput sequencing suggest that these structures form at a large number of regions with no such canonical G4-forming signatures. Many G4-binding proteins have been described with no evidence for any protein that binds to and stabilizes G4s...
March 14, 2024: Oncotarget
https://read.qxmd.com/read/38484150/correction-sigma-1-and-sigma-2-receptor-ligands-induce-apoptosis-and-autophagy-but-have-opposite-effect-on-cell-proliferation-in-uveal-melanoma
#24
Lucia Longhitano, Carlo Castruccio Castracani, Daniele Tibullo, Roberto Avola, Maria Viola, Giuliano Russo, Orazio Prezzavento, Agostino Marrazzo, Emanuele Amata, Michele Reibaldi, Antonio Longo, Andrea Russo, Nunziatina Laura Parrinello, Giovanni Li Volti
No abstract text is available yet for this article.
March 14, 2024: Oncotarget
https://read.qxmd.com/read/38441437/gz17-6-02-interacts-with-proteasome-inhibitors-to-kill-multiple-myeloma-cells
#25
JOURNAL ARTICLE
Laurence Booth, Jane L Roberts, Cameron West, Paul Dent
GZ17-6.02, a synthetically manufactured compound containing isovanillin, harmine and curcumin, has undergone phase I evaluation in patients with solid tumors (NCT03775525) with a recommended phase 2 dose (RP2D) of 375 mg PO BID. GZ17-6.02 was more efficacious as a single agent at killing multiple myeloma cells than had previously been observed in solid tumor cell types. GZ17-6.02 interacted with proteasome inhibitors in a greater than additive fashion to kill myeloma cells and alone it killed inhibitor-resistant cells to a similar extent...
March 5, 2024: Oncotarget
https://read.qxmd.com/read/38386842/correction-yk-4-279-effectively-antagonizes-ews-fli1-induced-leukemia-in-a-transgenic-mouse-model
#26
Tsion Zewdu Minas, Jenny Han, Tahereh Javaheri, Sung-Hyeok Hong, Michaela Schlederer, Yasemin Saygideğer-Kont, Haydar Çelik, Kristina M Mueller, Idil Temel, Metin Özdemirli, Heinrich Kovar, Hayriye Verda Erkizan, Jeffrey Toretsky, Lukas Kenner, Richard Moriggl, Aykut Üren
No abstract text is available yet for this article.
February 22, 2024: Oncotarget
https://read.qxmd.com/read/38386812/correction-combination-treatment-with-rucaparib-rubraca-and-mdm2-inhibitors-nutlin-3-and-rg7388-has-synergistic-and-dose-reduction-potential-in-ovarian-cancer
#27
Maryam Zanjirband, Nicola Curtin, Richard J Edmondson, John Lunec
No abstract text is available yet for this article.
February 22, 2024: Oncotarget
https://read.qxmd.com/read/38386807/prevalence-and-spectrum-of-germline-brca1-and-brca2-in-a-cohort-of-ovarian-cancer-patients-from-the-salento-peninsula-southern-italy-a-matter-of-preventive-health
#28
JOURNAL ARTICLE
Elisabetta De Matteis, Maria Rosaria Tumolo, Paolo Tarantino, Mariangela Ciccarese, Tiziana Grassi, Francesco Bagordo, Maria Rita De Giorgio, Emanuele Rizzo, Graziana Ronzino
OBJECTIVES: The aim of this exploratory, descriptive study was to characterize the deleterious BRCA1 and BRCA2 variants evaluated by genetic testing in a group of Ovarian cancer patients living in the Salento peninsula (Southern Italy). METHODS: From June 2014 to July 2023, patients with histologically confirmed high-grade serous carcinoma, fallopian tube, or primary peritoneal cancer who were referred to Lecce Familial Cancer Clinic were considered. BRCA-mutation genetic testing was performed on these patients...
February 22, 2024: Oncotarget
https://read.qxmd.com/read/38386805/sacituzumab-govitecan-plus-platinum-based-chemotherapy-mediates-significant-antitumor-effects-in-triple-negative-breast-urinary-bladder-and-small-cell-lung-carcinomas
#29
JOURNAL ARTICLE
Thomas M Cardillo, Maria B Zalath, Roberto Arrojo, Robert M Sharkey, Serengulam V Govindan, Chien-Hsing Chang, David M Goldenberg
Sacituzumab govitecan (SG) is an antibody-drug conjugate composed of an anti-Trop-2-directed antibody conjugated with the topoisomerase I inhibitory drug, SN-38, via a proprietary hydrolysable linker. SG has received United States Food and Drug Administration (FDA) approval to treat metastatic triple-negative breast cancer (TNBC), unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer, and accelerated approval for metastatic urothelial cancer...
February 22, 2024: Oncotarget
https://read.qxmd.com/read/38329733/retraction-multimodal-targeting-of-tumor-vasculature-and-cancer-stem-like-cells-in-sarcomas-with-vegf-a-inhibition-hif-1%C3%AE-inhibition-and-hypoxia-activated-chemotherapy
#30
Changhwan Yoon, Kevin K Chang, Jun Ho Lee, William D Tap, Charles P Hart, M Celeste Simon, Sam S Yoon
No abstract text is available yet for this article.
February 8, 2024: Oncotarget
https://read.qxmd.com/read/38329732/combining-causal-and-correlative-approaches-to-discover-biomarkers-of-response-to-paclitaxel
#31
JOURNAL ARTICLE
Alberto Moscona-Nissan, Karl J Habashy, Victor A Arrieta, Adam M Sonabend, Crismita Dmello
We recently discovered a putative paclitaxel response predictive biomarker for glioblastoma and breast cancer using the whole genome CRISPR knockout screen. The biomarker candidate was validated in two independent breast cancer patient cohorts that received taxane treatment. To further evaluate the potential application of this biomarker in the clinic for patients with glioblastoma, a prospective validation in cohorts of patients with glioblastoma is essential and will be performed as part of our ongoing phase II clinical trial (NCT04528680)...
February 8, 2024: Oncotarget
https://read.qxmd.com/read/38329728/gz17-6-02-interacts-with-bexarotene-to-kill-mycosis-fungoides-cells
#32
JOURNAL ARTICLE
Michael R Booth, Laurence Booth, Jane L Roberts, Cameron West, Paul Dent
GZ17-6.02, composed of curcumin, harmine and isovanillin, has undergone phase I evaluation in patients with solid tumors (NCT03775525) with an RP2D of 375 mg PO BID. The biology of GZ17-6.02 in malignant T cells and in particular those derived from mycosis fungoides (MF) patients, has not been studied. GZ17-6.02 alone and in combination with standard-of-care agents was effective in killing MF cells. All three components are necessary for optimal killing of MF cells. GZ17-6.02 activated ATM, the AMPK, NFκB and PERK and inactivated ERK1/2, AKT, ULK1, mTORC1, eIF2α, and reduced the expression of BCL-XL and MCL1...
February 8, 2024: Oncotarget
https://read.qxmd.com/read/38329731/neurotrophic-tyrosine-receptor-kinase-gene-fusion-in-papillary-thyroid-cancer-a-clinicogenomic-biobank-and-record-linkage-study-from-finland
#33
JOURNAL ARTICLE
Wei Zhang, Arndt A Schmitz, Roosa E Kallionpää, Merja Perälä, Niina Pitkänen, Mikko Tukiainen, Erika Alanne, Korinna Jöhrens, Renate Schulze-Rath, Bahman Farahmand, Jihong Zong
Selective tropomyosin receptor kinase (TRK) inhibitors are approved targeted therapies for patients with solid tumors harboring a neurotrophic tyrosine receptor kinase ( NTRK ) gene fusion. Country-specific estimates of NTRK gene fusion frequency, and knowledge on the characteristics of affected patients, are limited. We identified patients with histologically-confirmed papillary thyroid cancer (PTC) from Finland's Auria Biobank. TRK protein expression was determined by pan-TRK immunohistochemistry. Immuno-stained tumor samples were scored by a certified pathologist...
February 5, 2024: Oncotarget
https://read.qxmd.com/read/38329729/correction-targeting-programmed-cell-death-ligand-1-by-crispr-cas9-in-osteosarcoma-cells
#34
Yunfei Liao, Lulu Chen, Yong Feng, Jacson Shen, Yan Gao, Gregory Cote, Edwin Choy, David Harmon, Henry Mankin, Francis Hornicek, Zhenfeng Duan
No abstract text is available yet for this article.
February 5, 2024: Oncotarget
https://read.qxmd.com/read/38329726/genetic-and-therapeutic-landscapes-in-cohort-of-pancreatic-adenocarcinomas-next-generation-sequencing-and-machine-learning-for-full-tumor-exome-analysis
#35
JOURNAL ARTICLE
P A Shatalov, N A Falaleeva, E A Bykova, D O Korostin, V A Belova, A A Zabolotneva, A P Shinkarkina, A Yu Gorbachev, M B Potievskiy, V S Surkova, Zh V Khailova, N A Kulemin, Denis Baranovskii, A A Kostin, A D Kaprin, P V Shegai
About 7% of all cancer deaths are caused by pancreatic cancer (PCa). PCa is known for its lowest survival rates among all oncological diseases and heterogenic molecular profile. Enormous amount of genetic changes, including somatic mutations, exceeds the limits of routine clinical genetic laboratory tests and further stagnates the development of personalized treatments. We aimed to build a mutational landscape of PCa in the Russian population based on full exome next-generation sequencing (NGS) of the limited group of patients...
February 5, 2024: Oncotarget
https://read.qxmd.com/read/38329724/retraction-long-noncoding-rna-tug1-is-a-diagnostic-factor-in-lung-adenocarcinoma-and-suppresses-apoptosis-via-epigenetic-silencing-of-bax
#36
Huan Liu, Guizhi Zhou, Xin Fu, Haiyan Cui, Guangrui Pu, Yao Xiao, Wei Sun, Xinhua Dong, Libin Zhang, Sijia Cao, Guiqin Li, Xiaowei Wu, Xu Yang
No abstract text is available yet for this article.
February 5, 2024: Oncotarget
https://read.qxmd.com/read/38319731/preclinical-and-clinical-evaluation-of-the-janus-kinase-inhibitor-ruxolitinib-in-multiple-myeloma
#37
JOURNAL ARTICLE
Ashley Del Dosso, Elizabeth Tadevosyan, James R Berenson
Multiple myeloma (MM) is the most common primary malignancy of the bone marrow. No established curative treatment is currently available for patients diagnosed with MM. In recent years, new and more effective drugs have become available for the treatment of this B-cell malignancy. These new drugs have often been evaluated together and in combination with older agents. However, even these novel combinations eventually become ineffective; and, thus, novel therapeutic approaches are necessary to help overcome resistance to these treatments...
February 5, 2024: Oncotarget
https://read.qxmd.com/read/38275293/retraction-interferon-gamma-peptidomimetic-targeted-to-interstitial-myofibroblasts-attenuates-renal-fibrosis-after-unilateral-ureteral-obstruction-in-mice
#38
Fariba Poosti, Ruchi Bansal, Saleh Yazdani, Jai Prakash, Leonie Beljaars, Jacob van den Born, Martin H de Borst, Harry van Goor, Jan-Luuk Hillebrands, Klaas Poelstra
No abstract text is available yet for this article.
January 24, 2024: Oncotarget
https://read.qxmd.com/read/38275291/genetic-alterations-in-thyroid-cancer-mediating-both-resistance-to-braf-inhibition-and-anaplastic-transformation
#39
JOURNAL ARTICLE
Mark Lee, Luc Gt Morris
A subset of thyroid cancers present at advanced stage or with dedifferentiated histology and have limited response to standard therapy. Tumors harboring the BRAF V600E mutation may be treated with BRAF inhibitors; however, tumor response is often short lived due to multiple compensatory resistance mechanisms. One mode of resistance is the transition to an alternative cell state, which on rare occasions can correspond to tumor dedifferentiation. DNA sequencing and RNA expression profiling show that thyroid tumors that dedifferentiate after BRAF inhibition are enriched in known genetic alterations that mediate resistance to BRAF blockade, and may also drive tumor dedifferentiation, including mutations in the PI3K/AKT/MTOR ( PIK3CA , MTOR ), MAP/ERK ( MET , NF2 , NRAS , RASA1 ), SWI/SNF chromatin remodeling complex ( ARID2 , PBRM1 ), and JAK/STAT pathways ( JAK1 )...
January 24, 2024: Oncotarget
https://read.qxmd.com/read/38275290/the-fate-of-drug-discovery-in-academia-dumping-in-the-publication-landfill
#40
EDITORIAL
Uzma Saqib, Isaac S Demaree, Alexander G Obukhov, Mirza S Baig, Amiram Ariel, Krishnan Hajela
No abstract text is available yet for this article.
January 24, 2024: Oncotarget
journal
journal
43072
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.